{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:52:59Z","timestamp":1781653979072,"version":"3.54.5"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009886","name":"Regione Puglia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.biopha.2024.116877","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T08:09:15Z","timestamp":1717747755000},"page":"116877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Improvement of daratumumab- or elotuzumab-mediated NK cell activity by the bi-specific 4-1BB agonist, DARPin \u03b1-FAPx4\u20131BB: A preclinical study in multiple myeloma"],"prefix":"10.1016","volume":"176","author":[{"given":"Ilaria","family":"Saltarella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0545-3161","authenticated-orcid":false,"given":"Alexander","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelia","family":"Lamanuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6589-9625","authenticated-orcid":false,"given":"Christian","family":"Reichen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assunta","family":"Melaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Giovanni","family":"Solimando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Addolorata","family":"Mariggi\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Vacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonia","family":"Frassanito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Desaphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.116877_bib1","first-page":"137","article-title":"Hematological malignancies: myeloma","author":"Dimopoulos","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2024.116877_bib2","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1182\/blood-2011-01-270140","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies","author":"Korde","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.biopha.2024.116877_bib3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/cancers13040625","article-title":"The Immune Microenvironment in Multiple Myeloma: Friend or Foe?","author":"Lopes","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.116877_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood.V98.1.23","article-title":"Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients","author":"Kay","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2024.116877_bib5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","author":"Zelle-Rieser","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2024.116877_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.seminoncol.2022.01.004","article-title":"Harnessing natural killer cells for the treatment of multiple myeloma","author":"Clara","year":"2022","journal-title":"Semin Oncol."},{"key":"10.1016\/j.biopha.2024.116877_bib7","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3389\/fimmu.2017.01444","article-title":"Restoring natural killer cell immunity against multiple myeloma in the era of new drugs","volume":"8","author":"Pittari","year":"2017","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2024.116877_bib8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12032-007-0007-y","article-title":"Clinical stage-depending decrease of NK cell activity in multiple myeloma patients","author":"Jurisic","year":"2007","journal-title":"Med Oncol."},{"key":"10.1016\/j.biopha.2024.116877_bib9","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.3324\/haematol.2020.277525","article-title":"Myeloma natural killer cells are exhausted and have impaired regulation of activation","author":"D'Souza","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2024.116877_bib10","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3389\/fimmu.2019.01835","article-title":"The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment","author":"Monteran","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2024.116877_bib11","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/leu.2013.254","article-title":"Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies","author":"Frassanito","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2024.116877_bib12","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/leu.2015.289","article-title":"Halting pro-survival autophagy by TGF\u03b2 inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients","author":"Frassanito","year":"2016","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.biopha.2024.116877_bib13","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.3390\/cancers13194867","article-title":"Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity","author":"Suzuki","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.116877_bib14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2024.116877_bib15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.clml.2017.06.030","article-title":"Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future","author":"Sherbenou","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.biopha.2024.116877_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/cells9010167","article-title":"Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma","author":"Saltarella","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2024.116877_bib17","first-page":"171","article-title":"Drug resistance and minimal residual disease in multiple myeloma","author":"Gozzetti","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.biopha.2024.116877_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies","author":"Chester","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2024.116877_bib19","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2167189","article-title":"The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy","author":"Claus","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.biopha.2024.116877_bib20","article-title":"New emerging targets in cancer immunotherapy: CD137\/4-1BB costimulatory axis","author":"Etxeberria","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.biopha.2024.116877_bib21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40259-020-00429-8","article-title":"Beyond Antibodies: The DARPin\u00ae Drug Platform","author":"Stumpp","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.biopha.2024.116877_bib22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0022-2836(03)00896-9","article-title":"Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins","author":"Binz","year":"2003","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.biopha.2024.116877_bib23","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1538-7445.AM2020-2273","article-title":"Selection of first-in-human clinical dose range for the tumor-targeted 4-1BB agonist MP0310 (AMG 506) using a pharmacokinetic\/pharmacodynamics modeling approach","volume":"80","author":"Link","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2024.116877_bib24","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1158\/2326-6066.CIR-21-0553","article-title":"A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression","author":"Rigamonti","year":"2022","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.biopha.2024.116877_bib25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1107\/S0907444911007773","article-title":"Data processing and analysis with the autoPROC toolbox","author":"Vonrhein","year":"2011","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"10.1016\/j.biopha.2024.116877_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1107\/S0907444909047374","article-title":"Integration, scaling, space-group assignment and post-refinement","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"10.1016\/j.biopha.2024.116877_bib27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","author":"Winn","year":"2011","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"10.1016\/j.biopha.2024.116877_bib28","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"10.1016\/j.biopha.2024.116877_bib29","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/CJI.0b013e31818353e9","article-title":"A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy","author":"M\u00fcller","year":"2008","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.biopha.2024.116877_bib30","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2167189","article-title":"The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy","author":"Claus","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.biopha.2024.116877_bib31","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/protein\/gzx022","article-title":"Half-life extension using serum albumin-binding DARPin\u00ae domains","author":"Steiner","year":"2017","journal-title":"Protein Eng. Des. Sel."},{"issue":"1","key":"10.1016\/j.biopha.2024.116877_bib32","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1038\/s41467-018-07136-7","article-title":"Structure of the 4-1BB\/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab","author":"Chin","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2024.116877_bib33","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4161\/onci.19974","article-title":"Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody","author":"Houot","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biopha.2024.116877_bib34","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells","author":"Boyerinas","year":"2015","journal-title":"Cancer Immunol. Res"},{"issue":"19","key":"10.1016\/j.biopha.2024.116877_bib35","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.3390\/cancers13194867","article-title":"Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity","author":"Suzuki","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.biopha.2024.116877_bib36","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/cells11030392","article-title":"Harnessing the potential of NK cell-based immunotherapies against multiple myeloma","author":"Reina-Ortiz","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2024.116877_bib37","article-title":"Immunotherapy in multiple myeloma","volume":"29","author":"Jadoon","year":"2021","journal-title":"Cancer Treat. Res Commun."},{"key":"10.1016\/j.biopha.2024.116877_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1035276","article-title":"Current landscape and future directions of bispecific antibodies in cancer immunotherapy","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116877_bib39","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2167189","article-title":"The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy","author":"Claus","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.biopha.2024.116877_bib40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.biopha.2024.116877_bib41","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/cancers13040625","article-title":"The Immune Microenvironment in Multiple Myeloma: Friend or Foe?","author":"Lopes","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.116877_bib42","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood-2007-11-122465","article-title":"Fc-dependent expression of CD137 on human NK cells: insights into \"agonistic\" effects of anti-CD137 monoclonal antibodies","author":"Lin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2024.116877_bib43","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cpt.1961","article-title":"Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology","author":"Betts","year":"2020","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2024.116877_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.856961","article-title":"Physiological Considerations for Modeling in vivo Antibody-Target Interactions","volume":"13","author":"Dunlap","year":"2022","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2024.116877_bib45","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3390\/cancers6031363","article-title":"Cancer associated fibroblasts and tumor growth: focus on multiple myeloma","author":"De Veirman","year":"2014","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.116877_bib46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.seminoncol.2022.01.004","article-title":"Harnessing natural killer cells for the treatment of multiple myeloma","author":"Clara","year":"2022","journal-title":"Semin Oncol."},{"key":"10.1016\/j.biopha.2024.116877_bib47","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12032-007-0007-y","article-title":"Clinical stage-depending decrease of NK cell activity in multiple myeloma patients","author":"Jurisic","year":"2007","journal-title":"Med Oncol."},{"key":"10.1016\/j.biopha.2024.116877_bib48","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1699-0463.1991.tb05159.x","article-title":"Immune dysfunction in multiple myeloma. Reduced natural killer cell activity and increased levels of soluble interleukin-2 receptors","author":"Nielsen","year":"1991","journal-title":"APMIS"},{"key":"10.1016\/j.biopha.2024.116877_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2022.101544","article-title":"Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma","volume":"71","author":"Keruakous","year":"2022","journal-title":"Transpl. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116877_bib50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: from basic biology to clinical development","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2024.116877_bib51","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo-Expanded Autologous NK Cells","author":"Wang","year":"2018","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2024.116877_bib52","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","author":"Casneuf","year":"2017","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.biopha.2024.116877_bib53","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1599636","article-title":"Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells","volume":"1599636","author":"Ochoa","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biopha.2024.116877_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.970290","article-title":"Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity","volume":"13","author":"Reitinger","year":"2022","journal-title":"Front Immunol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224007613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224007613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:02:11Z","timestamp":1781650931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224007613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":54,"alternative-id":["S0753332224007613"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116877","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvement of daratumumab- or elotuzumab-mediated NK cell activity by the bi-specific 4-1BB agonist, DARPin \u03b1-FAPx4\u20131BB: A preclinical study in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116877","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116877"}}